 |
AbbVie |
ABBV-368 |
Biodrugs/ Drugs |
Cancer |
Head cancer / Neck cancer |
1PhI |
ABBV-368
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-066 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Psoriasis / Psoriatic arthritis / Crohn disease / Ulcerative colitis / Hidrosadenitis Supurativa |
3PhIII |
ABT-066
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABT-199/GDC0199 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Chronic Lymphocytic Leukemia / Mieloma Multiple / Leucemia Mieloide Aguda |
3PhIII |
ABT-199/GDC0199
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
AbbVie |
ABT-333 |
Biodrugs/ Drugs |
Infections |
C Hepatitis |
3PhIII |
ABT-333
Therapeutic area:
Infections
|
|
AbbVie |
ABT-493 |
Biodrugs/ Drugs |
Infections |
C Hepatitis |
3PhIII |
ABT-493
Therapeutic area:
Infections
|
|
AbbVie |
ABT-530 |
Biodrugs/ Drugs |
Infections |
C Hepatitis |
3PhIII |
ABT-530
Therapeutic area:
Infections
|
|
AbbVie |
ABT450/ABT-267 |
Biodrugs/ Drugs |
Infections |
C Hepatitis |
3PhIII |
ABT450/ABT-267
Therapeutic area:
Infections
|
|
AbbVie |
ABT-SLV187 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
4Reg. |
ABT-SLV187
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABT-555 |
Biodrugs/ Drugs |
Central Nervous System |
Ischemic stroke / Spinal cord injury |
2PhII |
ABT-555
Therapeutic area:
Central Nervous System
|
|
AbbVie |
Veliparib |
Biodrugs/ Drugs |
Cancer |
Breast Cancer / Ovarian cancer |
3PhIII |
Veliparib
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-399 |
Biodrugs/ Drugs |
Cancer |
NSCLC |
2PhII |
ABBV-399
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-263 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Myelofibrosis |
3PhIII |
ABT-263
Therapeutic area:
Blood and Lymphatic systems
|
|
AbbVie |
ABBV-951 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
3PhIII |
ABBV-951
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABBV-323 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
ABBV-323
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-181 |
Biodrugs/ Drugs |
Cancer |
Solid tumors / Head cancer / Neck cancer |
1PhI |
ABBV-181
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-621 |
Biodrugs/ Drugs |
Cancer |
Colorrectal cancer / Acute Myeloid Leukemia |
1PhI |
ABBV-621
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-494 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthritis / Chron Disease / Ulcerative Colitis/ Atopic Dermatitis / Psoriasic Arthritis / Axial Spondiloarthritis / Giant Cell Artheritis / Juvenil
Idiopatic Arthritis / Lupus / Ankylosing Spondylitis |
3PhIII |
ABT-494
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
Humira (adalimumab) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Hidradenitis Suppurativa / Uveitis / Ulcerative colitis/ Chron Disease / Rheumatoid Arthritis / Psoriasis / Psoriatic Arthritis |
4Reg. |
Humira (adalimumab)
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-8E12 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer |
2PhII |
ABBV-8E12
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABBV-647 |
Biodrugs/ Drugs |
Cancer |
Lung cancer |
1PhI |
ABBV-647
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-927 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
ABBV-927
Therapeutic area:
Cancer
|
 |
Amgen |
Evolocumab |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia |
4Reg. |
Evolocumab
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Amgen |
Romiplostim |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP) |
4Reg. |
Romiplostim
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
Talimogene laherparepvec |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma |
4Reg. |
Talimogene laherparepvec
Therapeutic area:
Cancer
|
|
Amgen |
Cinacalcet |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT |
4Reg. |
Cinacalcet
Therapeutic area:
Autoimmune & Inflammation / Kidney and Genitourinary system
|
|
Amgen |
Etelcalcetide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Secondary Hyperparathyroidism |
4Reg. |
Etelcalcetide
Therapeutic area:
Metabolic / Endocrinology
|
|
Amgen |
Romosozumab |
Biodrugs/ Drugs |
Musculoskeletal Disorders
Women´s health |
Postmenopausal osteoporosis |
3PhIII |
Romosozumab
Therapeutic area:
Musculoskeletal Disorders / Women´s health
|
|
Amgen |
Denosumab |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer |
4Reg. |
Denosumab
Therapeutic area:
Musculoskeletal Disorders
|
|
Amgen |
Blinatumomab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute lymphoblastic leukaemia |
4Reg. |
Blinatumomab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
Denosumab |
Biodrugs/ Drugs |
Cancer |
Giant cell tumour of the bone |
2PhII |
Denosumab
Therapeutic area:
Cancer
|
|
Amgen |
Omecantiv mecarbil |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Heart failure |
3PhIII |
Omecantiv mecarbil
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Celgene |
CC 486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Breast: Metastatic
Non-small cell lung: Advanced
Myelodysplastic Syndromes (MDS): post hypomethylating agent (HMA) failure |
2PhII |
CC 486
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CD19 CAR-T (JCAR017) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Aggressive large B-cell lymphoma: Relapsed/refractory |
1PhI |
CD19 CAR-T (JCAR017)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
VIDAZA® (azacitidine for injection) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute myeloid laeukemia (AML) (>30% blasts) |
4Reg. |
VIDAZA® (azacitidine for injection)
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-93269 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
1PhI |
CC-93269
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CC 486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma |
1PhI |
CC 486
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
Morgensen (GED-0301) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Ulcerative colitis |
2PhII |
Morgensen (GED-0301)
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Celgene |
PD-L1 Inhibitor: durvalumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML) |
2PhII |
PD-L1 Inhibitor: durvalumab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
REVLIMID® (lenalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse large B-cell lymphoma (ABC subtype): First line
Indolent lymphoma: relapsed/refractory
Follicular lymphoma: first line |
3PhIII |
REVLIMID® (lenalidomide)
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Myelodysplastic Syndromes (MDS): lower-risk
Post-induction AML maintenance |
3PhIII |
CC-486
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Primary Sclerosing Cholangit |
2PhII |
GS-9674 (FXR Agonist)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
Simtuzumab |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Idiopathic pulmonary fibrosis |
2PhII |
Simtuzumab
Therapeutic area:
Respiratory and Pulmonary system
|
|
Gilead Sciences |
Emtricitabine/Tenofovir alafenamide FDC |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-4875 (TPL2 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Inflammatory Bowel |
1PhI |
GS-4875 (TPL2 inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
KITE-718 ( MAGE A3/A6) |
Biodrugs/ Drugs |
Cancer |
Solid tumor. |
1PhI |
KITE-718 ( MAGE A3/A6)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
GS-0976 ( ACC Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
2PhII |
GS-0976 ( ACC Inhibitor)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR
Therapeutic area:
Infections
|
|
Gilead Sciences |
Remdesivir ( Gs-5734, Nuc. Inhibitor) |
Biodrugs/ Drugs |
Infections |
Ebola Virus infection |
2PhII |
Remdesivir ( Gs-5734, Nuc. Inhibitor)
Therapeutic area:
Infections
|
|
Gilead Sciences |
Andecaliximab (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Gastric cancer |
3PhIII |
Andecaliximab (MMP9 mAb inhibitor)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Filgotinib (JAK1 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid Arthritis |
3PhIII |
Filgotinib (JAK1 inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Vestalimod ( GS-9620, TRL-7 agonist) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
Vestalimod ( GS-9620, TRL-7 agonist)
Therapeutic area:
Infections
|
|
Gilead Sciences |
Andecaliximab (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
Andecaliximab (MMP9 mAb inhibitor)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
GS-5806 (fusion inhibitor) |
Biodrugs/ Drugs |
Infections
Respiratory and Pulmonary system |
Respiratory syncytial virus |
2PhII |
GS-5806 (fusion inhibitor)
Therapeutic area:
Infections / Respiratory and Pulmonary system
|
|
Gilead Sciences |
Filgotinib (JAK1 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Crohn's Disease and Ulcerative colitis |
2PhII |
Filgotinib (JAK1 inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
GS-62'7 (capsid inhibitor) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
GS-62'7 (capsid inhibitor)
Therapeutic area:
Infections
|
|
Gilead Sciences |
Entosplenitib (Syk inhibitor) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Hematological malignances |
2PhII |
Entosplenitib (Syk inhibitor)
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
GS-6615 (late sodium current inhibitor) |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Ventricular tachycardia / Ventricular fibrillation |
2PhII |
GS-6615 (late sodium current inhibitor)
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Gilead Sciences |
Presatovir ( Fusion inhibitor) |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Respiratory Syncytial Virus |
2PhII |
Presatovir ( Fusion inhibitor)
Therapeutic area:
Respiratory and Pulmonary system
|
|
Gilead Sciences |
GS-9131 (NRTI) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
GS-9131 (NRTI)
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-9722 (bNab) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
GS-9722 (bNab)
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-4997 (ASK-1 inhibitor) |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Pulmonary arterial hypertension |
2PhII |
GS-4997 (ASK-1 inhibitor)
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Gilead Sciences |
GS-9876 ( Syk Inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Sjogren's Syndrome |
2PhII |
GS-9876 ( Syk Inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir |
Biodrugs/ Drugs |
Infections |
HIV/AIDS - PreExposure Profilaxis |
3PhIII |
Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir
Therapeutic area:
Infections
|
|
Gilead Sciences |
ERK Inhibitor |
Biodrugs/ Drugs |
Cancer |
Cancer |
1PhI |
ERK Inhibitor
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Axicabtagene ciloleucel |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
DLBCL ,PMBCL & TFL |
3PhIII |
Axicabtagene ciloleucel
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
GS-9688 (TLR-8 Agonist) |
Biodrugs/ Drugs |
Infections |
HBV |
1PhI |
GS-9688 (TLR-8 Agonist)
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-5745 (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
GS-5745 (MMP9 mAb inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
GS-9876 (Syk inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Lupus |
2PhII |
GS-9876 (Syk inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Alafenamide STR |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Alafenamide STR
Therapeutic area:
Infections
|
|
Gilead Sciences |
Axicabtagene colileucel |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Indolent NHL |
2PhII |
Axicabtagene colileucel
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Selonsertib ( ASK-1 Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
3PhIII |
Selonsertib ( ASK-1 Inhibitor)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
GS-5745 (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2PhII |
GS-5745 (MMP9 mAb inhibitor)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
MCL |
2PhII |
KTE-C19
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Tirabrutinib (BTK inhibitor) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
B-cell malignancies |
2PhII |
Tirabrutinib (BTK inhibitor)
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Selonsertib ( ASK-1 Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Alcoholic Hepatitis |
2PhII |
Selonsertib ( ASK-1 Inhibitor)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
Momelotinib |
Biodrugs/ Drugs |
Cancer |
Pancreatic cancer |
2PhII |
Momelotinib
Therapeutic area:
Cancer
|
|
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Adult ALL |
1PhI |
KTE-C19
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
2PhII |
GS-9674 (FXR Agonist)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
GS-4997 (ASK-1 inhibitor) |
Biodrugs/ Drugs |
Digestive System |
Nonalcoholic steatohaepatitis |
2PhII |
GS-4997 (ASK-1 inhibitor)
Therapeutic area:
Digestive System
|
|
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Pedriatic ALL |
1PhI |
KTE-C19
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Primary Bilinary Cirrhosis |
2PhII |
GS-9674 (FXR Agonist)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
Simtuzumab |
Biodrugs/ Drugs |
Digestive System |
Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis |
2PhII |
Simtuzumab
Therapeutic area:
Digestive System
|
|
Gilead Sciences |
KITE-585 ( anti-BCMA) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
MM |
1PhI |
KITE-585 ( anti-BCMA)
Therapeutic area:
Blood and Lymphatic systems
|
 |
Incyte Biosciences Iberia |
INCAGN1876 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Discovery alliance with Agenus) |
2PhII |
INCAGN1876
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
Cholangiocarcinoma |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
8p11 MPN |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Follicular lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Marginal zone lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Mantle cell lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
MSI-H endometrial cancer (In collaboration with MacroGenics) |
1PhI |
INCMGA0012
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
Merkel cell carcinoma (In collaboration with MacroGenics) |
2PhII |
INCMGA0012
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
Anal cancer (In collaboration with MacroGenics) |
2PhII |
INCMGA0012
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Chronic graft-versus-host disease |
3PhIII |
Itacitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer (with osimertinib) (In collaboration with AstraZeneca) |
2PhII |
Itacitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCB01158 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Co-development with Calithera) |
2PhII |
INCB01158
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
Bladder cancer |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
 |
Merck KGaA |
Avelumab |
Biodrugs/ Drugs |
Cancer |
anti-PD-L1 mAb. Non-small cell lung cancer 1L |
3PhIII |
Avelumab
Therapeutic area:
Cancer
|
|
Merck KGaA |
Abituzumab |
Biodrugs/ Drugs |
Cancer |
pan-αν integrin inhibiting mAb. Colorectal Cancer 1L |
2PhII |
Abituzumab
Therapeutic area:
Cancer
|
|
Merck KGaA |
M4344 |
Biodrugs/ Drugs |
Cancer |
ATR inhibitor. Solid tumors |
1PhI |
M4344
Therapeutic area:
Cancer
|
|
Merck KGaA |
Avelumab |
Biodrugs/ Drugs |
Cancer |
anti-PD-L1 mAb. Urothelial cancer 1L-M |
4Reg. |
Avelumab
Therapeutic area:
Cancer
|
|
Merck KGaA |
Atacicept |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Anti-BlyS/APRIL fusion protein. Systemic lupus erythematosus / IgA nephropathy |
2PhII |
Atacicept
Therapeutic area:
Autoimmune & Inflammation
|
|
Merck KGaA |
M8891 |
Biodrugs/ Drugs |
Cancer |
MetAP2 inhibitor. Solid tumors |
1PhI |
M8891
Therapeutic area:
Cancer
|
|
Merck KGaA |
M5049 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
TLR7/8 antagonist. Immunology |
1PhI |
M5049
Therapeutic area:
Autoimmune & Inflammation
|
|
Merck KGaA |
Avelumab |
Biodrugs/ Drugs |
Cancer |
anti-PD-L1 mAb. Several types of cancer (Merkel cell cancer 1L / urothelial cancer / solid tumors and non-small cell lung cancer 1L in combination with talazoparib, axitinib, ALK inhibitors, cetuximab, or chemotherapy). |
2PhII |
Avelumab
Therapeutic area:
Cancer
|
|
Merck KGaA |
Tepotinib |
Biodrugs/ Drugs |
Cancer |
MET kinase inhibitor. Non-small cell lung cancer |
2PhII |
Tepotinib
Therapeutic area:
Cancer
|
|
Merck KGaA |
M6495 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
anti-ADAMTS-5 nanobody. Osteoarthritis |
1PhI |
M6495
Therapeutic area:
Autoimmune & Inflammation
|
|
Merck KGaA |
Bintrafusp alfa |
Biodrugs/ Drugs |
Cancer |
TGFbeta trap/anti-PD-L1. Solid tumors |
1PhI |
Bintrafusp alfa
Therapeutic area:
Cancer
|
|
Merck KGaA |
Sprifermin |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
fibroblast growth factor 18. Osteoarthritis |
2PhII |
Sprifermin
Therapeutic area:
Autoimmune & Inflammation
|
|
Merck KGaA |
M3258 |
Biodrugs/ Drugs |
Cancer |
LMP7 inhibitor. Multiple myeloma |
1PhI |
M3258
Therapeutic area:
Cancer
|
|
Merck KGaA |
M9241 (NHS-IL12) |
Biodrugs/ Drugs |
Cancer |
Cancer immunotherapy. Solid tumors in combination with avelumab |
1PhI |
M9241 (NHS-IL12)
Therapeutic area:
Cancer
|
|
Merck KGaA |
Peposertib (M3814) |
Biodrugs/ Drugs |
Cancer |
DNA-PK inhibitor. Solid tumors in combination with avelumab |
1PhI |
Peposertib (M3814)
Therapeutic area:
Cancer
|
|
Merck KGaA |
M1095 (ALX-0761) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
anti-IL-17 A/F nanobody. Psoriasis |
2PhII |
M1095 (ALX-0761)
Therapeutic area:
Autoimmune & Inflammation
|
|
Merck KGaA |
Peposertib (M3814) |
Biodrugs/ Drugs |
Cancer |
DNA-PK inhibitor. Rectal cancer |
2PhII |
Peposertib (M3814)
Therapeutic area:
Cancer
|
|
Merck KGaA |
Bintrafusp alfa |
Biodrugs/ Drugs |
Cancer |
TGFbeta trap/anti-PD-L1. Non-small cell lung cancer 1L / 1L/2L / Locally advanced non-small cell lung cancer / Biliary tract cancer 1L / Biliary tract cancer 2L / Cervical cancer 2L |
2PhII |
Bintrafusp alfa
Therapeutic area:
Cancer
|
|
Merck KGaA |
Berzosertib (M6620) |
Biodrugs/ Drugs |
Cancer |
ATR inhibitor. Solid tumors |
1PhI |
Berzosertib (M6620)
Therapeutic area:
Cancer
|
|
Merck KGaA |
M5717 |
Biodrugs/ Drugs |
Infections |
PeEF2 inhibitor. Malaria |
1PhI |
M5717
Therapeutic area:
Infections
|
|
Merck KGaA |
M1774 |
Biodrugs/ Drugs |
Cancer |
ATR inhibitor. Solid tumors |
1PhI |
M1774
Therapeutic area:
Cancer
|
|
Merck KGaA |
Tepotinib |
Biodrugs/ Drugs |
Cancer |
MET kinase inhibitor. Non-small cell lung cancer, METex14 skipping |
4Reg. |
Tepotinib
Therapeutic area:
Cancer
|
|
Merck KGaA |
Evobrutinib |
Biodrugs/ Drugs |
Central Nervous System |
BTK inhibitor. Multiple sclerosis |
3PhIII |
Evobrutinib
Therapeutic area:
Central Nervous System
|
 |
MSD |
Pembrolizumab/MK-7684 |
Biodrugs/ Drugs |
Cancer |
Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors. |
2PhII |
Pembrolizumab/MK-7684
Therapeutic area:
Cancer
|
|
MSD |
MK3475/Enfortumab |
Biodrugs/ Drugs |
Cancer |
Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer. |
3PhIII |
MK3475/Enfortumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Neoadjuvant treatment Platinum Doublet Chemotherapy +/-Pembrolizumab followed by Surgery |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
V937 in Combination with Pembrolizumab Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma |
2PhII |
CAVATAK/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Olaparib/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Olaparib in combination with Pembrolizumab in Participants with solid tumors Previously Treated |
2PhII |
Olaparib/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
first Line Study of Pembrolizumab +/- Ipilimumab in NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Solid Tumors Analyzed for Predictive Biomarkers. |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK6482 |
Biodrugs/ Drugs |
Cancer |
MK-6482 Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumor (pNET). |
2PhII |
MK6482
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Gardasil 9 |
Vaccines |
Infections |
VPH in preadolescents and adolescents |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. |
3PhIII |
Posaconazole
Therapeutic area:
Infections
|
|
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
V937 as Monotherapy or in Combination with Pembrolizumab in Participants With BCG-Unresponsive High-Risk NMIBC |
2PhII |
CAVATAK/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum |
Biodrugs/ Drugs |
Cancer |
Platform trial: Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or CarboplatinThe first-line treatment of participants with extensive-stage small cell lung cancer. |
2PhII |
Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum
Therapeutic area:
Cancer
|
|
MSD |
Gardasil 9 |
Vaccines |
Infections |
9vHPV vaccine in adult males 20 to 45 years of age |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma treatment naïve |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced melanoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Molnupiravir |
Biodrugs/ Drugs |
Infections |
Molnupiravir in non-hospitalized patients with COVID-19. |
3PhIII |
Molnupiravir
Therapeutic area:
Infections
|
|
MSD |
MK1308A (quavonlimab+pembro) |
Biodrugs/ Drugs |
Cancer |
A phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-
3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in
Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient
(dMMR) Stage IV Colo |
2PhII |
MK1308A (quavonlimab+pembro)
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase II, Pembrolizumab combined with chemotherapy as a First line treatment for NSCLC. |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Islatravir |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Islatravir
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Triple-Negative Breast Cancer (mTNBC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Phase III Pembro + Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Chemo +/- Pembrolizumab as Perioperative Therapy for Resectable Stage IIB or IIIA Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Versus Placebo in Surgically Resected or Ablated HCC Patients |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/MK-7684 or MK-4830 or MK-5890 |
Biodrugs/ Drugs |
Cancer |
Umbrella trial in First Line Metastatic non-squamous and squamous Non-small Cell Lung Cancer Subjects with pembrolizumab and MK-7684 or MK-4830 and in previously treated PD-1/PDL-1 patients receiving pembrolizumab and MK-5890 or MK-4830 |
2PhII |
Pembrolizumab/MK-7684 or MK-4830 or MK-5890
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/ Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + lenvatinib por previously untreated advanced or metastatic nccRCC. |
2PhII |
Pembrolizumab/ Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of Chemotherapy with or without Pembrolizumab in TKI-resistant EGFR-mutated Tumors in Metastatic Non-Squamous Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
V160 |
Vaccines |
Infections |
Prevention CMVin women 16-35 dosis vx 3 dosis |
2PhII |
V160
Therapeutic area:
Infections
|
|
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of ITu V937 in Combination with Pembrolizumab selected solid tumors |
2PhII |
CAVATAK/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab / Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib , Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung |
3PhIII |
Pembrolizumab / Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Trastuzumab + Chemotherapy with/without Pembrolizumab as First-line Treatment in Participants With HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of ITu V937 in Combination with Pembrolizumab selected solid tumors. |
2PhII |
CAVATAK/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for Second Line Therapy of Advanced melanoma post anti-PD1b inhibitor |
2PhII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line study of pembrolizumab +/- epacadostat in NSCLC |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Umbrella trial of Immune and Targeted Combination Therapies as First Line treatment in Renal Clear Cell Carcinoma subjects with MK1308A + Lenvatinib or MK 4280A + Lenvatinib or MK 6482 + Pembrolizumab + Lenvatinib vs Pembrolizumab + Lenvatinib or as Secon |
2PhII |
MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
MK4280A (favezelimab+pembro) |
Biodrugs/ Drugs |
Cancer |
A Phase 3 study of MK-4280A [co-formulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)] Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer. |
3PhIII |
MK4280A (favezelimab+pembro)
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase II (biomarker directed) Pembrolizumab Based Combination Therapy for Advanced Non-Small Cell Lung Cancer |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Selected Advanced Solid Tumors. |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
10 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Anacetrapib |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease |
3PhIII |
Anacetrapib
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line etoposide/platinum with or without pembrolizumab in extensive stage small cell lung cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell transplantation (HSCT) |
2PhII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
MK4830 |
Biodrugs/ Drugs |
Cancer |
MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors |
1PhI |
MK4830
Therapeutic area:
Cancer
|
|
MSD |
MK6482 + lenvatinib / cabozantinib |
Biodrugs/ Drugs |
Cancer |
MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for
Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy. |
3PhIII |
MK6482 + lenvatinib / cabozantinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Lenvatinib/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma |
3PhIII |
Lenvatinib/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Adjuvant chemotherapy plus pembrolizumab/placebo for endometrial cancer
after surgery with curative intent. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Lenvatinib/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma. |
3PhIII |
Lenvatinib/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pneumococcal vaccine polyvalent |
Vaccines |
Infections |
Paedriatric Prevention of pneumococal infection with V114 |
3PhIII |
Pneumococcal vaccine polyvalent
Therapeutic area:
Infections
|
|
MSD |
Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib in Participants with solid tumors Previously Treated |
2PhII |
Olaparib
Therapeutic area:
Cancer
|
|
MSD |
MK4830 |
Biodrugs/ Drugs |
Cancer |
MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors. |
1PhI |
MK4830
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
RSV Vaccine |
Biodrugs/ Drugs |
Infections |
VRS prevention in preterm infants |
2PhII |
RSV Vaccine
Therapeutic area:
Infections
|
|
MSD |
Mavezelimab/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
Mavezelimab/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK6482 |
Biodrugs/ Drugs |
Cancer |
MK-0482 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors. |
1PhI |
MK6482
Therapeutic area:
Cancer
|
|
MSD |
Gefapixant |
Biodrugs/ Drugs |
Women´s health |
Moderate to Severe Endometriosis-related Pain |
2PhII |
Gefapixant
Therapeutic area:
Women´s health
|
|
MSD |
pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (in Combination with MK-6482 and Lenvatinib, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment for ccRCC. |
3PhIII |
pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
ZINPLAVA |
Biodrugs/ Drugs |
Infections |
In Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection (Toxin B) |
3PhIII |
ZINPLAVA
Therapeutic area:
Infections
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients |
1PhI |
ZERBAXA
Therapeutic area:
Respiratory and Pulmonary system
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with Daratumumab in subjects Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with recurrent ovarian cancer |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Vericiguat |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Heart failure with reduced ejection Fraction |
3PhIII |
Vericiguat
Therapeutic area:
Cardiovascular and circulatory systems
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Adjuvant Therapy with Pembrolizumab Vs. Placebo in Resected Stage II Melanoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Selected Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
20 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pomalidomide and low dose dexamethasone with pembrolizumab in refractory or relapsed Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK1454/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Intratumoral MK-1454 plus Pembrolizumab First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma |
2PhII |
MK1454/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK-1308A/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular Carcinoma. |
2PhII |
MK-1308A/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Lenvatinib/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for Second Line Therapy of recurrent/metastatic head and neck squamous cell carcinoma have progressed after platinum therapy and post anti-PD1b inhibitor. |
2PhII |
Lenvatinib/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in advanced Merkel Cell Carcinoma (MCC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib in combination with Pembrolizumab in Participants with solid tumors Previously Treated. |
2PhII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
MK-5890/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Selected Advanced Solid Tumors. |
1PhI |
MK-5890/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab plus Epacadostat vs SOC (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subcutaneous Injection Versus Intravenous Infusion in Participants with Advanced Melanoma. |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase III Pembro + Chemotherapy in Persistent, Recurrent or Metastatic Cervical Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembro Combination Dose Escalation/MTD (IT)-Solid tumour-Rigontec GmbH-INTRATUMOR |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Chemoradiotherapy With or Without Pembrolizumab for the Treatment of
High-risk, Locally Advanced Cervical Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
PD-L1 Strong Metastatic Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/TACE |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma |
3PhIII |
Pembrolizumab/TACE
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Phase III Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Solid Tumors Analyzed for Predictive Biomarkers |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
HIF-2α inhibitor |
Biodrugs/ Drugs |
Cancer |
MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies |
3PhIII |
HIF-2α inhibitor
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-genera |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
MK-3655 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
MK-3655 in Individuals with Pre-Cirrhotic Nonalcoholic Steatohepatitis. |
2PhII |
MK-3655
Therapeutic area:
Metabolic / Endocrinology
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced/Unresectable or Metastatic Urothelial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK1454/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Intratumoral MK-1454 plus Pembrolizumab First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma. |
2PhII |
MK1454/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab with or without Chemotherapy as First-line Treatment in Participants With HER2 negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/MK-7684 or MK-4830 or MK-5890 |
Biodrugs/ Drugs |
Cancer |
Umbrella trial in First Line Metastatic non-squamous and squamous Non-small Cell Lung Cancer Subjects with pembrolizumab and MK-7684 or MK-4830 and in previously treated PD-1/PDL-1 patients receiving pembrolizumab and MK-5890 or MK-4830. |
2PhII |
Pembrolizumab/MK-7684 or MK-4830 or MK-5890
Therapeutic area:
Cancer
|
|
MSD |
Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies. |
2PhII |
Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Inactivated VZV Vaccine |
Vaccines |
Blood and Lymphatic systems
Cancer |
Adult Patients with Solid Tumor or Hematologic Malignancy |
3PhIII |
Inactivated VZV Vaccine
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
MSD |
Pembrolizumab/ Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib in Combination with Pembrolizumab in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment. |
3PhIII |
Pembrolizumab/ Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Phase III first line chemotherapy plus pembrolizumab + olaparib for BRCA non-mutated advanced EOC (epitelial ovarian cancer) |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab administrated with Platinum doublet chemotherapy in Metastasic Squamous or Nonsquamous non small cell lung cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
1st Line mTNBC choice of Taxane +/- Pembro-Triple negative breast cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
BET Inhibitor |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
BET Inhibitor
Therapeutic area:
Cancer
|
|
MSD |
Anti CTLA-4/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MK-1308 in Combination with Pembrolizumab vs MK1308 alone in Subjects with Advanced Solid Tumors (Melanoma Expansion Phase) |
2PhII |
Anti CTLA-4/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Pediatric subjects with nosocomial pneumonia (HABP/VABP) |
1PhI |
ZERBAXA
Therapeutic area:
Infections
|
|
MSD |
RECARBRIO (mk7655A) |
Biodrugs/ Drugs |
Infections |
Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection |
3PhIII |
RECARBRIO (mk7655A)
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-genera |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + lenvatinib versus docetaxel for metastatic Non-Small Cell Lung Cancer after platinum doublet chemotherapy and immunotherapy |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with metastatic Castration-Resistant Prostate Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Efinopegdutide (MK-6024) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease. |
2PhII |
Efinopegdutide (MK-6024)
Therapeutic area:
Metabolic / Endocrinology
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Renal Cell Carcinoma (RCC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Sugammadex/BRIDION |
Biodrugs/ Drugs |
Others |
Anesthesiology. Reversal of Neuromuscular Blockade in Pediatric Population |
4Reg. |
Sugammadex/BRIDION
Therapeutic area:
Others
|
|
MSD |
Pembrolizumab/ Lenvatinib |
Biodrugs/ Drugs |
Cancer |
.Lenvatinib plus Pembrolizumab plus chemotherapy for the treatment of
Advanced/Metastatic gastroesophageal adenocarcinoma. |
3PhIII |
Pembrolizumab/ Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase III extension study for participants with advanced tumors in pembrolizumab trials |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/MK-7684 |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with anti-TIGIT or Pembrolizumab in combination with anti-TIGIT plus Docetaxel in metastasic non small lung cancer with progressive disease after treatment with a platinum doublet chemotherapy or immunotheraphy. |
2PhII |
Pembrolizumab/MK-7684
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in recurrent or metastatic cutaneous squamous cell carcinoma |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil as First Line treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
RIG-I |
Biodrugs/ Drugs |
Cancer |
Advanced/Metastatic or Recurrent Solid Tumors |
1PhI |
RIG-I
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK-5890/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Selected Advanced Solid Tumors |
1PhI |
MK-5890/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab as
Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for
Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell
Carcinoma (LA HNSCC) |
4Reg. |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with metastatic Castration-Resistant Prostate Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + Chemotherapy + Radiotherapy in Stage III NSCLC |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Chemotherapy-Naïve metastatic Castration-Resistant Prostate Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280 |
Biodrugs/ Drugs |
Cancer |
Platform trial: Pembrolizumab in Combination with Investigational Agents in PD-1/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy. |
2PhII |
Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
ER+Neoadjuvant -Breast-Oestrogen receptor positive breast cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Gefapixant |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Chronic cough |
3PhIII |
Gefapixant
Therapeutic area:
Respiratory and Pulmonary system
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib Compared with Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III No |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Doravirine |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Doravirine
Therapeutic area:
Infections
|
|
MSD |
Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies |
2PhII |
Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia |
1PhI |
Posaconazole
Therapeutic area:
Infections
|
|
MSD |
Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib Monotherapy in Participants with Previously
Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous
Recombination Deficiency (HRD) Positive Advanced Cancer. |
2PhII |
Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Chemotherapy-Naïve metastatic Castration-Resistant Prostate Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for Squamous Non Small cell Lung cancer |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer. Pembro +/- Lenvatinib |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab or Placebo Plus Enzalutamide/ADT in subjects with Metastatic Hormono-Senmsitive Prostate Cancer (mHSPC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Peri-operative Pembrolizumab + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy for Cis-Eligible MIBC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Favezelimab/Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects with Advanced Solid Tumor. |
1PhI |
Favezelimab/Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) and Relapsed or Refractory Richter Syndrome |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced HCC |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Prevention of CMV disease in D+/R- kidney transplant recipients |
3PhIII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
Golimumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Non-radiographic axial Spondyloarthritis |
4Reg. |
Golimumab
Therapeutic area:
Autoimmune & Inflammation
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer. |
2PhII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab or Placebo Plus Enzalutamide/ADT in subjects with Metastatic Hormono-Senmsitive Prostate Cancer (mHSPC). |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for non Squamous Non Small cell Lubng cancer |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib vs Olaparib + Bevacizumab vs 5FU + Bevacizumab
in metastasic colorectal cancer |
3PhIII |
Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer. Pembro +/- Epacadostat |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
High-risk Non Muscle Invassive Bladder Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab vs chemotherapy in patients with advanced melanoma |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Perioperative Pembrolizumab for Cis-Ineligible MIBC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
V-937/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors. |
2PhII |
V-937/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
15-valent Pneumococcal Conjugate Vaccine |
Vaccines |
Infections |
Pneumoccoco in healthy adults 50 years of age or older |
3PhIII |
15-valent Pneumococcal Conjugate Vaccine
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Peri-operative Pembrolizumab + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy for Cis-Eligible MIBC. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Pediatric Subjects with Complicated Intra-Abdominal Infection |
2PhII |
ZERBAXA
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Versus Placebo as Adjuvant Therapy in High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects
with Advanced Solid Tumors. |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
High-risk Non Muscle Invassive Bladder Cancer. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Stereotactic Body Radiotherapy (SBRT) with Pembrolizumab or Placebo |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Lenvatinib/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for Second Line Therapy of recurrent/metastatic head and neck squamous cell carcinoma have progressed after platinum therapy and post anti-PD1b inhibitor |
2PhII |
Lenvatinib/Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients |
3PhIII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib/Belzutifan |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors. |
2PhII |
Pembrolizumab/Lenvatinib/Belzutifan
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Perioperative Pembrolizumab for Cis-Ineligible MIBC. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in children and young adults with newly diagnosed Classical Hodgkin Lymphoma |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors |
2PhII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Progressive or recurrent Intermediate or High risk, Non-muscle invasive Urothelial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
 |
Novo Nordisk Pharma |
AM833 (amilyn analogue) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
AM833 (amilyn analogue)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
G530L (glucagon analogue/liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
G530L (glucagon analogue/liraglutide)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Semaglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
PYY1562 (analogue peptid YY) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
PYY1562 (analogue peptid YY)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Liraglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 in paediatric population |
3PhIII |
Liraglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Nonacog beta pegol |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia B |
4Reg. |
Nonacog beta pegol
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
Monoclonal antibody anti Il-21 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 |
2PhII |
Monoclonal antibody anti Il-21
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
N8-GP (glycopegylated recombinant FVIII) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
3PhIII |
N8-GP (glycopegylated recombinant FVIII)
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
Oral semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Oral semaglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Faster-acting insulin aspart (FIAsp) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and type 2 |
4Reg. |
Faster-acting insulin aspart (FIAsp)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Insulin LA287 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
Insulin LA287
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Somapacitan(Long-acting growth hormone) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Growth hormone deficiency |
3PhIII |
Somapacitan(Long-acting growth hormone)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
IDegAsp (combination insulin degludec + insulin aspart) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 and type 1 |
4Reg. |
IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Semaglutide NASH |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Non-alcoholic steatohepatitis |
2PhII |
Semaglutide NASH
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Concizumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A and B |
2PhII |
Concizumab
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
IDegLira (combination insulin degludec + liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
4Reg. |
IDegLira (combination insulin degludec + liraglutide)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Prandial Bioedge |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
Prandial Bioedge
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Liraglutide 3mg |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
4Reg. |
Liraglutide 3mg
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Semaglutide obesidad |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
3PhIII |
Semaglutide obesidad
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Turoctocog alfa |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
4Reg. |
Turoctocog alfa
Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
ulcerative colitis |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
BRAF KIN INH (2) |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
BRAF KIN INH (2)
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
2PhII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Acute myocardial infarction |
3PhIII |
DALCETRAPIB
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
ALEGLITAZAR
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
herceptin |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
4Reg. |
herceptin
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
plasma cell neoplasm |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
VANUCIZUMAB
Therapeutic area:
Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
1PhI |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
BASIMGLURANT |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Fragile X Syndrome |
2PhII |
BASIMGLURANT
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Malignant neoplasms of lymphoid haematopoietic + |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lungs |
4Reg. |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site. |
4Reg. |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
BET |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
1PhI |
BET
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
PATECLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
PATECLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
CD40 IMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CD40 IMAB
Therapeutic area:
Cancer
|
|
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
IGF1R MAB
Therapeutic area:
Cancer
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
4Reg. |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
FAP 4-1BBL iMAb |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
FAP 4-1BBL iMAb
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
3PhIII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
CEA IL2V |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA IL2V
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
DALCETRAPIB
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
3PhIII |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
CMV ANTI |
Biodrugs/ Drugs |
Infections |
Cytomegaloviral disease |
2PhII |
CMV ANTI
Therapeutic area:
Infections
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Breast Cancer |
3PhIII |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Other + unspecif. types of non-Hodgkin's lymphoma |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
IL22 Fc |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Other disorders involving the immune mechanism |
1PhI |
IL22 Fc
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
ALPHA7 NIC AGO |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
ALPHA7 NIC AGO
Therapeutic area:
Central Nervous System
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
OX40 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
4Reg. |
OX40
Therapeutic area:
Cancer
|
|
Roche |
cadherin-11 MAb |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthritis |
2PhII |
cadherin-11 MAb
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
2PhII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
POLATUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
2PhII |
POLATUZUMAB VEDOTIN
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA CD3 TCB
Therapeutic area:
Cancer
|
|
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
IGF1R MAB
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
FAP IL2V FP |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
FAP IL2V FP
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
triple negative breast cancer |
3PhIII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
PARSATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
PARSATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
HCV POL INH PRO |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
HCV POL INH PRO
Therapeutic area:
Infections
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Irritable bowel syndrome |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
CRENEZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
CRENEZUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
Venclexta |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's Lymphoma |
2PhII |
Venclexta
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
PEGASYS |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
PEGASYS
Therapeutic area:
Infections
|
|
Roche |
IL22 Fc |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
IL22 Fc
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Renal cell carcinoma |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
ANTI-INFLUENZA A |
Biodrugs/ Drugs |
Infections |
Influenza |
2PhII |
ANTI-INFLUENZA A
Therapeutic area:
Infections
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
POLATUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
3PhIII |
POLATUZUMAB VEDOTIN
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
1PhI |
CD20 CD3 TDB
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Colorectal cancer |
3PhIII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
CIF MEK INH |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CIF MEK INH
Therapeutic area:
Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
VENETOCLAX
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
FAP IL2V FP |
Biodrugs/ Drugs |
Cancer |
non-Small cell lung cancer |
2PhII |
FAP IL2V FP
Therapeutic area:
Cancer
|
|
Roche |
MIRCERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Chronic renal failure anemia |
2PhII |
MIRCERA
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
LAMPALIZUMAB |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinal disorders other |
4Reg. |
LAMPALIZUMAB
Therapeutic area:
Ophthalmology and optometry
|
|
Roche |
GANTENERUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
GANTENERUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
DANOPREVIR |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
DANOPREVIR
Therapeutic area:
Infections
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
Venclexta |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoid leukaemia |
3PhIII |
Venclexta
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
TAMIFLU |
Biodrugs/ Drugs |
Infections |
Influenza |
1PhI |
TAMIFLU
Therapeutic area:
Infections
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Giant Cel arteritis |
3PhIII |
ACTEMRA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
triple negative breast cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of cervix uteri |
2PhII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
selicrelumab |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
selicrelumab
Therapeutic area:
Cancer
|
|
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Malignant neoplams of lymphoid haematopoietic |
1PhI |
CD20 CD3 TDB
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
4Reg. |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of pancreas |
2PhII |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
EM MS BIOMARKER |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
EM MS BIOMARKER
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
XOLAIR |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Dermatitis (Allergic Contact) |
3PhIII |
XOLAIR
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic lupus erythematosus |
2PhII |
GAZYVA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
mPI3K alpha inh |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1PhI |
mPI3K alpha inh
Therapeutic area:
Cancer
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Other malignant neoplasms of skin |
1PhI |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
PICTILISIB
Therapeutic area:
Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Other necrotizing vasculopathies |
3PhIII |
MABTHERA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Systemic lupus erythematosus |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
4Reg. |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
TASPOGLUTIDE |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
TASPOGLUTIDE
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthristis ( juvenile) |
4Reg. |
ACTEMRA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
TIRAGOLUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
TIRAGOLUMAB
Therapeutic area:
Cancer
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
ERIVEDGE
Therapeutic area:
Cancer
|
|
Roche |
SMN2 splicer (2) |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Spinal muscular atrophy and related syndromes |
3PhIII |
SMN2 splicer (2)
Therapeutic area:
Musculoskeletal Disorders
|
|
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Non-hodgkin's lymphoma |
1PhI |
CD20 CD3 TDB
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
XELODA
Therapeutic area:
Cancer
|
|
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LIFASTUZUMAB VEDOTIN
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Other disorders involving the immune mechanism |
3PhIII |
ACTEMRA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
other unspecificed types of non-hodgkin's lymphoma |
2PhII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
HEMLIBRA |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
3PhIII |
HEMLIBRA
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
SERD (2) |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1PhI |
SERD (2)
Therapeutic area:
Cancer
|
|
Roche |
EM RA PRED DEV |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
EM RA PRED DEV
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
PICTILISIB
Therapeutic area:
Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Pemphigus |
3PhIII |
MABTHERA
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Roche |
TIRAGOLUMAB |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
2PhII |
TIRAGOLUMAB
Therapeutic area:
Cancer
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ERIVEDGE
Therapeutic area:
Cancer
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
VALCYTE |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Transplanted organ and tissue status (Excl. complications) |
3PhIII |
VALCYTE
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
MabThera |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Follicular ( nodular) non-hodgkin's lymphoma |
3PhIII |
MabThera
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic sclerosis |
3PhIII |
ACTEMRA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of prostate |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Peripheral Vascular Diseases |
3PhIII |
ACTEMRA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
Tau Mab (37D3) |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
Tau Mab (37D3)
Therapeutic area:
Central Nervous System
|
|
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
colorectal cancer |
1PhI |
CEA CD3 TCB
Therapeutic area:
Cancer
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Metastases |
2PhII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
OX40 |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
OX40
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Ovarian cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
herceptin |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
3PhIII |
herceptin
Therapeutic area:
Cancer
|
|
Roche |
SERD(3) (9545) |
Biodrugs/ Drugs |
Cancer |
breast cancer metastatic |
1PhI |
SERD(3) (9545)
Therapeutic area:
Cancer
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
SEMBRAGILINE |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
SEMBRAGILINE
Therapeutic area:
Central Nervous System
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
VEFG- ANG2 Bsb |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinal disorders other |
3PhIII |
VEFG- ANG2 Bsb
Therapeutic area:
Ophthalmology and optometry
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cancer |
Other disorders involving the immune mechanism |
2PhII |
ERIVEDGE
Therapeutic area:
Autoimmune & Inflammation / Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
EM ACTEMAB RA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
EM ACTEMAB RA
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
3PhIII |
XELODA
Therapeutic area:
Cancer
|
|
Roche |
Myostatin |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Duchenne muscular dystrophy |
3PhIII |
Myostatin
Therapeutic area:
Musculoskeletal Disorders
|
|
Roche |
PLGF MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PLGF MAB
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Thyrotoxicosis (hyperthyroidism) |
3PhIII |
ACTEMRA
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
ALECTINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ALECTINIB
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
breast cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
Pancreatic cancer |
1PhI |
CEA CD3 TCB
Therapeutic area:
Cancer
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Plasma cell neoplasm |
2PhII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
Asyn MAb |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson's disease |
2PhII |
Asyn MAb
Therapeutic area:
Central Nervous System
|
|
Roche |
XOLAIR |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
other diseases of upper respiratory tract |
3PhIII |
XOLAIR
Therapeutic area:
Respiratory and Pulmonary system
|
|
Roche |
FORTOVASE |
Biodrugs/ Drugs |
Infections |
HIV disease unspecified |
2PhII |
FORTOVASE
Therapeutic area:
Infections
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
2PhII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
3PhIII |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Multiple Sclerosis |
4Reg. |
OCREVUS
Therapeutic area:
Central Nervous System
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
BITOPERTIN |
Biodrugs/ Drugs |
Central Nervous System |
Schizophrenia |
3PhIII |
BITOPERTIN
Therapeutic area:
Central Nervous System
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Head and neck cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
CEACAM5 CEA TCB |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
CEACAM5 CEA TCB
Therapeutic area:
Cancer
|
|
Roche |
Esbriet |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Idiophatic pulmonary fibrosis |
2PhII |
Esbriet
Therapeutic area:
Respiratory and Pulmonary system
|
|
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Primary progresive multiple sclerosis |
3PhIII |
OCREVUS
Therapeutic area:
Central Nervous System
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
breast cancer |
4Reg. |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
ALECENSA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ALECENSA
Therapeutic area:
Cancer
|
|
Roche |
HERCEPTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
2PhII |
HERCEPTIN
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and unspecified parts of biliary tract |
3PhIII |
GAZYVA
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
3PhIII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
FENEBRUTINIB |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic lupus erythematosus |
2PhII |
FENEBRUTINIB
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
LEBRIKIZUMAB |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Other diseases of upper respiratory tract |
2PhII |
LEBRIKIZUMAB
Therapeutic area:
Respiratory and Pulmonary system
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Musculoskeletal Disorders |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Hepatocellular carcinoma |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
Cergutuzumab amunaleukin |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
Cergutuzumab amunaleukin
Therapeutic area:
Cancer
|
|
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Relapsing-remitting multiple sclerosis |
3PhIII |
OCREVUS
Therapeutic area:
Central Nervous System
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Cervical cancer |
2PhII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
ALECENSA |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer |
4Reg. |
ALECENSA
Therapeutic area:
Cancer
|
|
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
2PhII |
LIFASTUZUMAB VEDOTIN
Therapeutic area:
Cancer
|
|
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
VANUCIZUMAB
Therapeutic area:
Cancer
|
|
Roche |
GPC3 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of liver |
2PhII |
GPC3 MAB
Therapeutic area:
Cancer
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
Idasanutlin |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Leukaemia Acute |
3PhIII |
Idasanutlin
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
MERICITABINE |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
MERICITABINE
Therapeutic area:
Infections
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
ALEGLITAZAR
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
kidney cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
DSTA4637S |
Biodrugs/ Drugs |
Infections |
Bacterial infection of unespecified site |
1PhI |
DSTA4637S
Therapeutic area:
Infections
|
|
Roche |
OCREVUS |
Biodrugs/ Drugs |
Cancer |
Renal cancer carncinoma |
3PhIII |
OCREVUS
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Colorectal cancer |
2PhII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
Balovaptan |
Biodrugs/ Drugs |
Central Nervous System |
Autism |
3PhIII |
Balovaptan
Therapeutic area:
Central Nervous System
|
|
Roche |
NEORECORMON |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Anaemia in neoplastic disease |
2PhII |
NEORECORMON
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
1PhI |
VENETOCLAX
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
HPV16 TI |
Biodrugs/ Drugs |
Infections |
Viral agents as cause of diseases classified to other |
2PhII |
HPV16 TI
Therapeutic area:
Infections
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|